.png){kind=icon}
.png){kind=icon}
Return
Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis
.png){kind=icon}
OA
AI
M
J
S
D
DOI：10.1002/alz.71308.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate value-based prices (VBPs) for lecanemab and donanemab across 174 countries.
Keywords:
Alzheimer's disease
cost-effectiveness analysis
decision-analytic modeling
dementia
disease-modifying therapies
donanemab
economic evaluation
lecanemab
threshold analysis
value-based pricing
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
A
IF:
0
Papers:
511
Citations:
0
View more organizations